# q04 rev 0 - raw independent returns

tested_sha256: 8fe853cdc7576ec1210f27b2813ae35d006efccd89c3827004d910005650ce62
Date: 2026-10-05. Runtime: Claude Code (VS Code), fresh Agent-tool subagents (Opus 5.5), each given
only the workspace root, its own packet path and the frozen question (closed-book: question only).
Returns below are the agents' final reports as delivered, unedited.

## Solver B (blind-solver, packet solver-2)

answer: Two products, both with a CE Mark. In date order:
1. TactiFlex™ Duo Ablation Catheter, Sensor Enabled™: CE Mark, announced January 2026.
2. Libre® Duo, a dual glucose-ketone biowearable sensor: CE Mark, announced May 2026.

confidence: high

path:
1. D07, the Q4/full-year 2025 release dated Jan. 22, 2026 (text/D07.txt line 39, matching the original docs/abt_ex991_2026-01-22.txt line 37): "In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy..." The release is dated January 22, so "January" means January 2026.
2. D10, the Q2 2026 release dated July 16, 2026 (text/D10.txt line 35, matching the original line 33): "In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor." The release covers the quarter ended June 30, 2026, so this is May 2026. The release came out in July, but the announcement it describes was made in May, which is inside the window.
3. Items excluded:
   - D07 line 37: "In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System." This was December 2025, before the window.
   - D10 line 37: "In May, Abbott completed its submission to the U.S. ... FDA seeking approval for the company's Amulet™ 360..." This is a submission, not an approval. D08 line 35 (February) reports early VERITAS study results for the "investigational Amulet 360™", which is also not an approval.
   - D10 line 39: in May, the American Cancer Society updated its guidelines and "reaffirmed Cologuard® and Cologuard Plus®". The ACS is a medical society, not a regulator, so this is not a regulatory approval.
   - D08: the AtaCor collaboration (January), FreeDM2 trial results (March) and the Exact Sciences acquisition closing (March 23). D10: TECTONIC trial enrollment (April) and late-breaking trial data at the Heart Rhythm Society meeting (April). None of these is a product approval.
   - D09 (April 17, 2026) is a court notice about the proposed derivative-litigation settlement, with "Court approval" pending a June 4, 2026 hearing. It is not about a product.
   - D11 (August 2026) covers preterm infant formula litigation and contains no product approvals.
   - The 2025 approvals are all outside the window: Volt CE Mark, March 2025 (D02 line 29); Tendyne FDA approval, May 2025 (D03 line 37); TriClip approval in Japan, July 2025, and Navitor CE Mark for an expanded indication, August 2025 (D04 lines 33 and 35).
4. A search of both text/ and docs/ for approv, CE Mark, FDA, clearance, secured, obtained, granted, indication, label and coverage found no other approval in January–June 2026.

minimal_documents: D07 and D10. Neither can be replaced: TactiFlex Duo appears only in D07 and Libre Duo only in D10, and D08 (Q1 2026) lists no approvals.

readings:
- Counting only documents dated January–June 2026 (D07, D08, D09): TactiFlex Duo only, because the Libre Duo item comes from D10, dated July 16.
- Treating the Jan. 22, 2026 release as a fresh announcement of its "two significant regulatory approvals" (D07 line 35): Volt PFA System (FDA, December 2025), then TactiFlex Duo (January 2026), then Libre Duo (May 2026). I think this reading is weaker, because D07 itself says the Volt approval was announced in December.
- If "regulatory approval" were stretched to include guideline endorsements: Cologuard and Cologuard Plus (May 2026) would be added. I reject this because the ACS is not a regulator.

gaps:
- The packet gives only months ("In January", "In May"), not exact days, so the order rests on months.
- The text files have "[... characters not shown ...]" gaps, but only inside financial table rows. The originals I compared show the same highlight bullets.
- Coverage: D07–D11 read in full. D05 read for its first 60 lines plus search; D06 (the by-laws, effective Dec. 12, 2025) read for its header plus search; D01–D04 checked by search only. All of these predate 2026, so they cannot report a January–June 2026 announcement.
- The manifest lists text extraction with no pages, and the packet has no layout files or PDFs, so no page-level check was possible.
- I did not read question.txt, as instructed.

contaminated: no

Relevant files: solver-2\text\D07.txt, D10.txt, D08.txt (under the run folder).

## Solver A (blind-solver, packet solver-1)

I found two qualifying products, both with a CE Mark.

answer: 1) TactiFlex Duo Ablation Catheter, Sensor Enabled: CE Mark, announced January 2026. 2) Libre Duo, a dual glucose-ketone biowearable sensor: CE Mark, announced May 2026. No other regulatory approval, including from the FDA, was announced in that window.

confidence: high

path:
1. D07 (Q4 2025 earnings release, docs/abt_ex991_2026-01-22.txt), line 19: "ABBOTT PARK, Ill., Jan. 22, 2026". Line 39: "In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation." Because the release is dated Jan. 22, 2026, "January" means January 2026. This is in the window.
2. D07, line 37: "In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System". That was December 2025, so it falls outside the window and is excluded.
3. D08 (Q1 2026 release, dated April 16, 2026), lines 33-37. The quarter's highlights are a collaboration with AtaCor (January), early VERITAS results for the "investigational Amulet 360™" (February) and FreeDM2 trial results (March). None is an approval. Its other "approv" hits are only the standard MDR/IVDR "previously approved products" footnotes.
4. D10 (Q2 2026 release, line 21: "July 16, 2026 … second quarter ended June 30, 2026"), line 35: "In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor." This is in the window.
5. Other items in D10 that are excluded:
   - Line 37: "completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360". This is a submission, not an approval.
   - Line 39: the American Cancer Society "reaffirmed Cologuard® and Cologuard Plus®". This is a screening guideline, not a regulatory approval.
   - Line 31: TECTONIC trial enrollment, and line 33: data presented at the HRS conference.
6. Other documents checked:
   - D09 (April 17, 2026) is a court notice about a shareholder settlement. Its "approval" means court approval of the settlement, with a hearing set for June 4, 2026. It is not about a product.
   - D11 (Aug. 20, 2026) is about preterm-formula litigation and contains no approvals. It is also outside the window.
   - D01-D05 are dated 2025. Their approvals are all from 2025: Volt CE Mark "In March" (D02), Tendyne FDA approval "In May" (D03), TriClip approval in Japan "In July" and Navitor CE Mark "In August" (D04). D05 mentions regulatory approvals for the Exact Sciences deal, which is not a product.
   - D06 is the company by-laws.
7. I compared the bullet points in the original docs/ files for D07, D08 and D10 with the text extraction, and they match.
8. Order by date: TactiFlex Duo (January 2026), then Libre Duo (May 2026).

minimal_documents: D07 and D10. D08 supports the claim that no approvals were announced in February or March. No other document in the packet could replace D07 or D10 for these two facts.

readings:
- **Counting by release date instead of announcement date.** Under this reading, the list is whatever appears in releases dated January to June 2026. That gives Volt PFA System (FDA, restated in the Jan. 22, 2026 release) and TactiFlex Duo. Libre Duo would drop out because it only appears in the July 16 release. This reading is weaker, because D07 dates Volt's announcement "In December" and D10 dates Libre Duo's "In May".
- **Including Volt because the January release repeats it.** This gives Volt PFA System, TactiFlex Duo, Libre Duo.

gaps:
- No exact day is given for either announcement, only "In January" (on or before Jan. 22) and "In May".
- The packet is plain text only (manifest shows method: text), so there are no PDF pages or .layout.txt files to check.
- The "[... characters not shown ...]" gaps are only inside the financial tables, not the highlights.
- D01-D06 were checked by keyword search and opening sections only, not read in full. All of them predate the window.
- Coverage is limited to what these filings report. Announcements made outside the earnings releases' highlights would not be captured.

contaminated: no. Only the packet's text/ and docs/ folders were read, and no answer or hint was in the inputs. I cannot check from inside this session how it was launched (whether it was a fork or which settings were used).

Key files: solver-1\text\D07.txt, D10.txt, D08.txt (under the run folder).

## Shortcut audit (shortcut-auditor, packet shortcut)

answer: Two products, both CE Marks. Abbott announced no FDA or other regulatory approvals in this window.
1. **January 2026:** CE Mark for the TactiFlex Duo Ablation Catheter, Sensor Enabled.
2. **May 2026:** CE Mark for the Libre Duo glucose-ketone biowearable sensor.

verdict: clear

shortest_path:
1. **D07 (Q4 2025 release, dated Jan. 22, 2026), line 39:** "In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™…" The release is dated January 22, 2026, so this January is in the window. The bullet just before it, "In December, Abbott announced U.S. … FDA approval for its Volt™ PFA System," is December 2025, so it is excluded.
2. **D08 (Q1 2026 release, Apr. 16, 2026), lines 33–37:** The Q1 highlights list only a partnership with AtaCor (January), early VERITAS study results for Amulet 360 (February) and FreeDM2 trial results (March). No approvals are listed, and the January TactiFlex Duo item is not repeated here.
3. **D10 (Q2 2026 release, July 16, 2026), line 35:** "In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor." The other Q2 bullets are not approvals:
   - Line 37: Amulet 360 was only submitted to the FDA "seeking approval."
   - Line 39: the Cologuard item is an American Cancer Society screening guideline, not a regulatory action.
4. Ordered by date: TactiFlex Duo (January), then Libre Duo (May).

sufficient_documents: D07 + D10 is the minimal set. D08 is needed to confirm nothing was added in February or March. No single document covers both items, and no first-half 2026 summary exists. Relying only on the Q1 and Q2 releases (D08 + D10) would miss TactiFlex Duo.

searches:
- **Terms searched across all text/ files:** "CE Mark", approv*, clearance/cleared, authoriz*, FDA, regulator, 510(k), indication, launch, Japan, China, Health Canada, PMDA, NMPA, secured, obtained, received, granted, breakthrough, label.
- **"CE Mark" hits:** only four in the whole packet: D02 (Volt, March 2025), D04 (Navitor, August 2025), D07 (TactiFlex Duo) and D10 (Libre Duo).
- **Read in full:** D07, D08, D09, D11 and the first 330 lines of D10. I searched the rest of D10, which matched only expense footnotes about EU device rules for "previously approved products."
- **Cross-checked against the original docs/ files** for the 2026 releases; the extracted text matches.
- **Other documents:** D06 is the bylaws (only corporate-governance approvals). D05's approvals are for the Exact Sciences deal closing. D09 is a court approval of a shareholder lawsuit settlement. D11 is a preterm formula litigation settlement (August 2026).
- **Same-month 2025 decoys found:** Volt CE Mark in March 2025 (D02), Tendyne FDA approval in May 2025 (D03), and TriClip Japan approval (July 2025) and Navitor expanded CE Mark (August 2025) in D04.
- I did not open question.txt in the packet root.

readings/gaps:
- **Alternative reading:** "announce between January and June" could be read as the release date. Then the answer would be Volt PFA (FDA) plus TactiFlex Duo, because D07 is dated January 2026, and Libre Duo would drop out because D10 is dated July 16. This reading is weaker: the releases themselves date each announcement ("In December," "In May"), which puts Volt in December 2025 and Libre Duo in May 2026.
- **Common misreadings to reject:**
  - Counting the Amulet 360 FDA submission as an approval.
  - Counting the Cologuard screening-guideline reaffirmation as a regulatory approval.
  - Counting the Exact Sciences deal clearances, which are not product approvals.
  - Mixing up "In May" in D03 (2025) with "In May" in D10 (2026).
- **Difficulty risk, not a shortcut:** a packet-wide "CE Mark" search plus a check of each release's date quickly finds both items. It is still a two-document join.
- **Gaps:**
  - The "[... characters not shown ...]" markers in text/ fall only inside sales tables.
  - The highlight lists are chosen by the company and are not exhaustive; D08 leaves out the January item. Approvals announced only in standalone press releases outside these filings cannot be ruled out from the packet.

Key files (under the run folder): shortcut\text\D07.txt (docs\abt_ex991_2026-01-22.txt), shortcut\text\D08.txt (docs\abt_ex991_2026-04-16.txt), shortcut\text\D10.txt (docs\abt_ex991_2026-07-16.txt).

## Closed-book (closed-book-solver, question text only)

answer: My best guess is the TactiFlex Duo pulsed field ablation catheter (U.S. FDA approval). I can't give a full, dated list for January to June 2026.
confidence: low
basis: I don't remember any specific Abbott announcements from January to June 2026, so this is a guess from Abbott's product timeline. I recall the Volt PFA System got its CE Mark in March 2025, and I think its U.S. approval came in late 2025, which would be outside this window. I also recall TactiFlex Duo's U.S. approval was expected in 2026. I can't confirm the dates, whether the list is complete, or whether other approvals or CE Marks were announced, such as for diabetes sensors or structural heart devices.
contaminated: no
